Search / Trial NCT00001437

Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis

Launched by NATIONAL CANCER INSTITUTE (NCI) · Dec 9, 2002

Apply for Trial

Trial Information

Current as of May 26, 2024

Completed

Keywords

Cytokines Fibrosis Intensity Post Radiation Fibrosis Radiation Injury Trental

Description

Patients with late fibrovascular sequelae of radiation or of combined radiation and surgery, with quantifiable symptomatology or disability, will be eligible for this trial. This protocol is designed as an open label one arm study. (A placebo controlled randomized trial was approved by the IRB but after extensive negotiation, drug and placebo in slow release formulation will not be provided by the manufacturer). Up to fifty patients will be recruited. After initial assessment of their condition by specified clinical and laboratory parameters, each of the patients will be treated for 8 weeks...

Gender

All

Eligibility criteria

  • POPULATION CHARACTERISTICS:
  • Regional advanced postradiation fibrosis of the neck, chest wall, pelvis, or extremities causing measurable impairment of specific function, i.e.: Decreased range of motion, Weakness, Sensory deficit, Pain requiring narcotics, Significantly altered activities of daily living.
  • None of these conditions present either before or during radiotherapy or attributed to surgery or chemotherapy.
  • Patients with prostate cancer allowed if prostate-specific antigen (PSA) is less than 4.0 ng/mL and the last 3 PSA values were stable or decreasing. Abnormal bone scan or film acceptable if consistent with degenerative disease.
  • No recurrent or metastatic cancer.
  • No concurrent second cancer.
  • PRIOR/CONCURRENT THERAPY: At least 3 months since pentoxifylline.
  • PATIENT CHARACTERISTICS:
  • Age: 18 and over.
  • Performance status: Karnofsky 70%-100% (unrelated to postradiation fibrosis).
  • CARDIOVASCULAR:
  • No symptomatic coronary artery disease with frequent anginal episodes necessitating any of the following during past 6 months: Coronary artery bypass, Angioplasty, Pacemaker placement, Thrombolytic treatment.
  • No chronic cardiac failure with persistent hemodynamic abnormality and ejection fraction less than 40%.
  • No coagulation, platelet, or vascular disorder that threatens to cause bleeding.
  • OTHER:
  • No intolerance to pentoxifylline or other xanthines (e.g., caffeine, theophylline, theobromine).
  • No seizure disorder.
  • No peptic ulcer disease.
  • Willing to undergo serial evaluations (excluding biopsies, laser Doppler, MRI) by NCI rehabilitation specialist for documentation and grading of functional disability.
  • No pregnant or nursing women.
  • Adequate contraception encouraged in fertile women.

Attachments

readout_NCT00001437_2024-05-26.pdf

4.5 MB

NCT00001437_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0